The case for & against
Bull & Bear analysis
Bullish
The Oncology Institute (NASDAQ: TOI) is an emerging player in the oncology healthcare sector, focusing on a value-based care model to provide high-quality treatment and integrated patient management. The company seeks to expand its specialization in oncology care through efficient operational management and an expanding specialty pharmacy division, emphasizing a strategic push into capitated contracts. With a unique blend of fee-for-service and capitated arrangements, TOI has endeavored to enhance patient outcomes while optimizing care delivery across multiple states, particularly Florida.
Bull says
- ↑Q1 revenue $147M, up 41% YoY, fueled by pharmacy growth.
- ↑Specialty pharmacy revenue $87.5M, +77.6% YoY, diversifying income.
- ↑Analysts rate TOI Strong Buy; $7.67 PT implies ~48% upside.
- ↑AI-driven workflows to cut ~$2M in expenses, boosting margins.
- ↑Management guides $5–$15M free cash flow for 2026.
- ↑Expanding capitated care across Florida strengthens value model.
Bear says
- ↓Earnings yield -0.97 indicates difficulty converting revenue to profit.
- ↓Adjusted EBITDA loss $2.4M vs. $5.1M loss YoY highlights weak margins.
- ↓Profitability metrics remain negative, signaling operational cost pressures.
- ↓Volatility factor +2.63 raises concerns over erratic share movements.
- ↓High leverage and declining institutional backing heighten financial risk.
- ↓Dependence on CMS model exposes revenue to regulatory shifts.
Earnings Call · Q1 2025 · Mgmt. Guidance
Updated 06-03-2026bullish
Transcript signals
Bull points
- I'm happy to report that revenue for Q1 increased by 10% versus the prior year period, driven by our retail pharmacy and dispensary business which continues to grow rapidly and set fill records, contributing 49.3 million in revenue and over 9 million in gross profit in Q1 alone, with this business segment growing over 20% in the first quarter of 2025 versus the prior year.
- we had a very strong start to the year with new capitated contract wins, adding over 80,000 lives in the first quarter on four agreements across the Florida, California, and Nevada markets. Anticipated new capitation contracts in the first half of 2025 are projected to add approximately $50 million in new revenue on an annualized basis.
- Our fee-for-service business also returned to growth in the quarter, growing 9% quarter-over-quarter and 2% year-over-year, highlighting the impact of our investments in referral relationship management and call center expansion.
Bear points
- we are outsourcing our clinical trials business to Helios Clinical Trials. Under the terms of the new arrangement, TOI will recognize revenue solely for our share of the profit, which will reduce our expected revenue for the year by $5 million.
Read full transcript analysis ›